A contemporary review of plasminogen activator inhibitor 1 in cardiovascular disease and broader disease state implications.

Mebeli Becerra, Neha Soogoor, Justin Vu, Jacob Wortley, Mohanakrishnan Sathyamoorthy

Department of Medicine, Burnett School of Medicine at Texas Christian University, Fort Worth, TX.Department of Medicine, Burnett School of Medicine at Texas Christian University, Fort Worth, TX. · pubmed

Paper

Abstract

Plasminogen activator inhibitor 1 (PAI-1) has well-described roles in cardiovascular disease states including clinical thrombosis, atherosclerosis, arteriosclerosis, and myocardial infarction. However, an evolving plethora of research associates PAI-1 with numerous other disease processes including inflammation and infection, diabetes, metabolic syndrome, neurodegeneration, and cancer. Aside from disease processes, PAI-1 has also recently been shown to be a key biomarker for aging with effects on skeletal muscle repair, cardiovascular health, and cellular senescence. This review provides a timely and comprehensive update of PAI-1's role in the pathogenesis of a diverse array of human diseases.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper discusses the role of plasminogen activator inhibitor 1 (PAI-1) as a key biomarker for aging and its implications for cellular senescence and cardiovascular health. This relevance stems from its focus on PAI-1's potential role in the underlying mechanisms of aging and age-related diseases, rather than merely addressing symptoms.

Author of this paper? Send a correction.